Karl Ernst Siegler

Pharmacokinetic and Pharmacodynamic Profile of New Biosimilar Filgrastim XM02 Equivalent to Marketed Filgrastim Neupogen®

Heinz Lubenau, Peter Bias, Anne-Katrin Maly et al. · BioDrugs · 2009 · 60 citations

Medicine, Pharmacokinetics, Pharmacology +10

What is the “Optimal” follow-up schedule for ICD patients?

Julia C. Senges–Becker, M KLOSTERMANN, R C Becker et al. · EP Europace · 2005 · 56 citations

Medicine, Cardiology, Cardiothoracic Surgery +14

The impact of different intensities of regular donor plasmapheresis on humoral and cellular immunity, red cell and iron metabolism, and cardiovascular risk markers

B. Tran‐Mi, H Storch, Kirsten Seidel et al. · Vox Sanguinis · 2004 · 54 citations

Life Sciences, Hematology, Immunology +12

Pharmacokinetics of Teneligliptin in Subjects With Renal Impairment

Atef Halabi, Haidar Maatouk, Karl Ernst Siegler et al. · Clinical Pharmacology in Drug Development · 2013 · 39 citations

Pharmacy, Pharmacokinetics, Pharmacology +15

The impact of intensive serial plasmapheresis and iron supplementation on iron metabolism and Hb concentration in menstruating women: a prospective randomized placebo‐controlled double‐blind study

Anne‐Marie Bier‐Ulrich, Hannelore Haubelt, Christof Anders et al. · Transfusion · 2003 · 31 citations · Full text

Medicine, Hematology, Nutritional Sciences +17